Emendo Biotherapeutics

Check out the latest BioBoss podcast hosted by John Simboli with this incredible person! Inspiring and interesting conversation covering entrepreneurship in the biotech space and especially #geneediting David Baram

Alliance for Regenerative Medicine’s #CGMesa23 is almost here! EmendoBio's Chief Business Officer, Rachel Diamant is excited to present on October 11 @3:45pm PST. The EmendoBio team is looking forward to connecting with senior executives and top stakeholders to discuss the challenges and opportunities in gene therapy. Learn more: https://bit.ly/3CzDKDS See you there! #EmendoBio #GeneTherapy

We are excited to announce that EmendoBio's President and Chief Executive Officer, David Baram, has made the first-ever Slice of Healthcare's 50 Under 50 list. Read more: https://bit.ly/3RPjfh8 #SoHC50Under50 #EmendoBio

We're in the midst of the next generation of gene editing. We're on our own mission to improve CRISPR-based editing, and we're so inspired by all of the cutting-edge research in this space, including this research on CRISPR-based engineering of RNA viruses. Amazing work by Artem Nemudryi and colleagues at Wiedenheft Lab x Montana State University. https://bit.ly/3rC7Syq #CRISPR #GeneEditing

EmendoBio President and CEO David Baram, PhD, will participate in a panel discussion at Chardan's 7th Annual Genetic Medicines Conference in New York on Oct 3. We look forward to connecting with leaders in the gene editing space and discussing the enormous investment opportunities in this growing industry. https://bit.ly/3ZtUBop #EmendoBio #ChardanGMConf

The last step of our approach is development, where a custom drug composition is developed and validated. Together, the three steps of our approach result in targeted gene editing solutions that put the disease and patients first. Learn more: https://bit.ly/3qJ5Hsz #EmendoBio #GeneEditing #PrecisionMedicine

“The future of genomic medicine continues to be an exciting and emerging topic of interindustry conversations critical to advancing the field as a whole.” In case you missed it, check out this article in Today's Clinical Lab by EmendoBio's co-founder and Chief Business Officer, Rachel Diamant, as she shares her insights on the past, present, and future of CRISPR. https://bit.ly/3Dshhej #EmendoBio #CRISPR #GenomicMedicine

Available CRISPR tools can seldom achieve the efficiency and precision to eliminate off-target effects and enable the highest level of precision, such as allele-specific editing Optimization is the second essential step of our approach to matching nucleases to diseases. Requiring a unique combination of protein engineering, guide design, and library selection, optimization helps our nucleases achieve even allele specificity while maintaining high activity with non-detectable off-target effects. Learn more: https://bit.ly/3KKLjxR #GeneEditing #PrecisionMedicine #EmendoBio

Meet Michal Avidan-Gartzman, EmendoBio Employee #1, and a member of the EmendoBio team since the company's inception. As the leader of EmendoBio's operations department, she has played a big role in EmendoBio's growth in the #GeneEditing space, creating an operational framework that supports our mission to make a lasting impact on healthcare and scientific progress. "We've left no stone unturned in ensuring excellence and compliance with industry standards, from procurement to safety standards. I'm excited about what the future holds for us and look forward to continuing this remarkable journey." #EmendoPowerhouse #GeneEditing